Cytokinetics, MD - Clinical Trial Investigator | Syfrah

Trials Sponsors Conditions Drugs Pricing

Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

DRUG(8)

MIXED(1)

phase_1phase_2_3

cytokinetics, cytokinetics-inc

Omecamtiv Mecarbil

Aficamten (5 - 20 mg)

cytokinetics-inc

CK-3773274 (5 - 15 mg)

CK-3773274 (10 - 30 mg)

8 unique interventions2 categories

Analytics

Trial Phases

Phase 12

Phase 22

Phase 33

Trial Status

Completed3

Terminated2

Other1

Role Distribution

Other Roles6

Activity Timeline

Clinical Trials (6)

NCT05924815Phase 1Completed

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Healthy Participants

StudydirectorStart date: 2023-05-15

NCT05662215Phase 1Terminated

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Healthy Participants

StudydirectorStart date: 2022-12-06

NCT04944784Phase 3Terminated

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

StudydirectorStart date: 2021-08-16

NCT04848506Phase 2/3Enrolling By Invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Symptomatic Hypertrophic Cardiomyopathy (HCM)

StudydirectorStart date: 2021-05-06

NCT04219826Phase 2Completed

Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy (HCM)

StudydirectorStart date: 2020-01-10

NCT03759392Phase 3Completed

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

Heart Failure With Reduced Ejection Fraction

StudydirectorStart date: 2019-04-09

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

CO

High-influence Collaborator

CO

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Healthy Volunteers2 Amyotrophic Lateral Sclerosis1 Heart Failure With Reduced Ejection Fraction1 Hypertrophic Cardiomyopathy (HCM)1 Symptomatic Hypertrophic Cardiomyopathy (HCM)1

Affiliations

Cytokinetics

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Paolo Bonato, PhD

Spaulding Rehabilitation Hospital

Shared therapeutic areas:

Healthy Volunteers

Similarity Score6%

Herbert B Slade, MD

Healthpoint

Shared therapeutic areas:

Healthy Volunteers

Similarity Score6%

loic MONDOLONI

Assistance Publique Hopitaux De Marseille

Shared therapeutic areas:

Amyotrophic Lateral Sclerosis

Similarity Score6%

Hamid Gourabi, PhD

head of Royan Institute

Shared therapeutic areas:

Amyotrophic Lateral Sclerosis

Similarity Score6%

Hagop Youssoufian, MD

Verastem, Inc.

Shared therapeutic areas:

Healthy Volunteers

Similarity Score6%

Sabine Hazan, MD

ProgenaBiome

Shared therapeutic areas:

Amyotrophic Lateral Sclerosis

Similarity Score6%

James C Eisenach, MD

Wake Forest University Health Sciences

Shared therapeutic areas:

Healthy Volunteers

Similarity Score6%

Suman Sheraz, PhD*

Riphah International University

Shared therapeutic areas:

Healthy Volunteers

Similarity Score6%

Urielle Desalbres

Assistance Publique Hôpitaux de Marseille

Shared therapeutic areas:

Amyotrophic Lateral Sclerosis

Similarity Score6%

Lorenzo Berra, MD

Massachusetts General Hospital

Shared therapeutic areas:

Healthy Volunteers

Similarity Score6%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT05924815Phase 1StudyDirector

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

Healthy Participants

Completed

NCT05662215Phase 1StudyDirector

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Healthy Participants

Terminated

NCT04944784Phase 3StudyDirector

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Terminated

NCT04848506Phase 2/3StudyDirector

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Symptomatic Hypertrophic Cardiomyopathy (HCM)

Enrolling By Invitation

NCT04219826Phase 2StudyDirector

Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

Hypertrophic Cardiomyopathy (HCM)

Completed

NCT03759392Phase 3StudyDirector

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

Heart Failure With Reduced Ejection Fraction

Completed

All 6 trials loaded